Table 2 Participants characteristics
Study | Mean age + SD (years) | Age range (years) | Male/Female (n/n) | Dialysis duration and frequency | Inclusion criteria | Exclusion criteria |
|---|---|---|---|---|---|---|
Cross-over with randomization | ||||||
Cianciolo et al. | 63.3 ± 7.2 | 42–72 | 21/19 | 4 h 3×/wk | chronic HD, age 18+, stable, AVF | gastrointestinal bleeding, acute cardiovascular event 3 months before, malignancy, coagulation disorders, DVT, immunosupressive therapy, acute vasculitis, liver disease, active infection, diabetes, enrolled in other clinical trial |
Klejna et al. | 68.2 | 44–82 | 11/10 | 4–5 h 3×/wk | Chronic HD | HIV, Hepatitis B, Hepatitis C, VTE, gastrointestinal bleeding, coagulation disorders |
Lord et al. | 66.6 ± 14.8 | NS | 17/15 | 4 h 3×/wk | Chronic HD | Patients with catheters, with bleeding diathesis in last 3 months, with thrombocytopenia, hepatic failure, oral anticoagulation (but not antiplatelets) |
Saltissi et al. | NS | 22–85 | 17/19 | 3–5 h 3×/wk | Chronic HD | bleeding disorders, anticoagulation therapy (warfarin, aspirin) |
Stefoni et al. | 63.7 ± 7 | NS | 39/15 | 4 h 3×/wk | Chronic HD for at least 12 months | active gastrointestinal bleeding, myeloproliferative disorders, malignant diseases, hereditary deficiency of coagulation factors, LAC phenomenon, antiphospholipid syndrome |
Cross-over without randomization | ||||||
Al-Saran et al. | 46.83 ± 14.63 | NS | 17/6 | 3–4 h 3×/wk | at least 6 months on HD prior to study | bleeding disorders, anemia with hemoglobin levels less than 10 g/dL, recent trauma, surgery, infectious disease or hemorrhagic disorder (< 1 month) in addition to those receiving oral or other forms of anticoagulant therapy (e.g. warfarin, aspirin), or drugs that could affect heparin activity (e.g. tetracyclines, digitalis, and antihistamines) |
Bambauer et al. | 60 | NS | 12/15 | NS | Chronic HD | NS |
Bramham et al. | 61 ± 15 | NS | 65/45 | 3–4 h 3×/wk | Chonic HD on monitoring shift | Renal transplant, transferred to satellite unit, switched to PD, on warfarin |
Deuber et al. (part 1) | 53 ± 7 | 47–65 | NS | 4 h 3×/wk | chronic HD for at least 18 months | NS |
Deuber et al. (part 2) | 50 ± 18 | 20–67 | NS | 4 h 3×/wk | chronic HD for at least 18 months | NS |
Kronenberg et al. | 44.7 ± 16.8 | NS | 13/11 | 3.5–5 h 3×/wk | in pre-dialysis | diabetes, bleeding disorders, oral anticoagulants, lipid lowering drugs |
Lai et al. | 42.2 ± 5.2 | 24–60 | 25/15 | 10–16 h/wk | Chronic HD | diabetes, primary hyperlipidemia |
Leu et al. | 57.8 ± 9.8 | NS | 7/13 | 4 h 3×/wk | Chronic HD at least 6 months | pts with lipid lowering drugs except non-diabetic pts. under lovastatin for >6 months, known hemorrhagic diathesis, low platelet count, liver insufficiency, hypersensitivity to heparin |
Schmitt et al. | 58.6 | 37–72 | 13/9 | 4–5.8 h | chronic HD, cholesterol >200 mg/dL | diabetes, concomittant drug treatment (lipid lowering drugs, COX inhibitors) |
Yang et al. (part 1) | 44 ± 15 | NS | 7/3 | 3×/wk | chronic HD, non diabetic | NS |
Yang et al. (part 2) | 57 ± 6.4 | NS | 7/3 | 3×/wk | chronic HD with diabetes type II | NS |
Parallel with randomization | ||||||
Elisaf et al. | NS | 15–61 | NS | 4 h 3×/wk | chronic HD | diabetes, hyperlipidemia (primary or secondary) |
Nurmohamed et al. | NS | NS | NS | 4–6 h 2-3×/wk | chronic HD | NS |
Schrader et al. | 54.0 ± 15.2 (LMWH) 51.6 ± 17.9 (UFH) | NS | 21/14 (LMWH) 19/16 (UFH) | NS | pre-HD requiring HD, not on heparin in prior 3 months | bleeding disorders, needed antiplatelets or anticoagulants |